CHMP rec­om­mends OK for Al­ny­lam's patisir­an; Am­gen scraps a BC­MA ADC

→ Al­ny­lam $AL­NY took an­oth­er big step to­ward get­ting a Eu­ro­pean ap­proval for patisir­an. The biotech says that the CHMP rec­om­mend­ed an OK for hered­i­tary transthyretin-me­di­at­ed amy­loi­do­sis (hAT­TR amy­loi­do­sis) in adult pa­tients with stage 1 or stage 2 polyneu­ropa­thy. A for­mal OK is like­ly. The drug is fac­ing an Au­gust 11 PDU­FA date at the FDA.

→ Por­to­la $PT­LA, though, isn’t mak­ing any head­way with be­trix­a­ban. The CHMP bat­ted back the com­pa­ny’s ap­peal of its ear­li­er re­jec­tion. Here’s a sum­ma­ry of all the ac­tion at the EMA to­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA